durvalumab

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
durvalumab

GtoPdb Ligand ID: 7985

Synonyms: anti-B7H1 monoclonal antibody | Imfinzi® | MEDI-4736 | MEDI4736

durvalumab is an approved drug (FDA (2017), EMA (2018))

Compound class: Antibody

Comment: Durvalumab is a monoclonal antibody directed against programmed death-1 ligand-1 (PD-L1, aka CD274), an important immunopharmacological drug discovery target in immuno-oncology.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. A patent search suggests that the development and use of durvalumab may be covered by patent WO2011066389 [2], although we cannot verify this by peptide sequence matches as no sequences from this patent are pulled in a protein BLAST with the light or heavy variable regions of durvalumab peptide sequences. An X-ray crystal structure of the PD-L1/durvalumab complex has been submitted to the RCSB PDB (accession 5X8M) [1].

No information available.

No information available.

Summary of Clinical Use
Durvalumab (MEDI-4736) was 'fast tracked' to Phase 3 clinical trial, then receiving full FDA approval in May 2017 for the treatment of advanced/metastatic bladder cancer (urothelial carcinoma) in patients who have already received platinum-containing chemotherapy. In February 2018 FDA approval was expanded to include treatment of some stage III non-small cell lung cancer (NSCLC) patients. It is hoped that durvalumab may show clinical efficacy against other cancers. Click here to link to ClinicalTrials.gov's list of Phase 2 and 3 studies evaluating MEDI-4736 in additional cancer types.

Summary of Clinical Use

Durvalumab (MEDI-4736) was 'fast tracked' to Phase 3 clinical trial, then receiving full FDA approval in May 2017 for the treatment of advanced/metastatic bladder cancer (urothelial carcinoma) in patients who have already received platinum-containing chemotherapy. In February 2018 FDA approval was expanded to include treatment of some stage III non-small cell lung cancer (NSCLC) patients. It is hoped that durvalumab may show clinical efficacy against other cancers. Click here to link to ClinicalTrials.gov's list of Phase 2 and 3 studies evaluating MEDI-4736 in additional cancer types.

Mechanism Of Action and Pharmacodynamic Effects
Anti-PD-L1 antibodies interfere with PD-L1 signalling, which results in the activation of tumour-detecting/infiltrating T cells. The drug’s mechanism of action enables the immune cells to detect and destroy tumour cells.

Mechanism Of Action and Pharmacodynamic Effects

Anti-PD-L1 antibodies interfere with PD-L1 signalling, which results in the activation of tumour-detecting/infiltrating T cells. The drug’s mechanism of action enables the immune cells to detect and destroy tumour cells.

External links
For extended ADME data see the following: Electronic Medicines Compendium (eMC) Drugs.com European Medicines Agency (EMA)

External links

For extended ADME data see the following:

Electronic Medicines Compendium (eMC)
Drugs.com
European Medicines Agency (EMA)